PRKAA2 and metabolic dysfunction-associated steatohepatitis: While we may have failed to accurately capture AMPK activation, importantly, there were no observable changes to steatosis, fibrosis or inflammation at this dose (data not shown), indicating that low (50 mpk in the water) dose metformin dose did not affect indicators of NASH progression in the CDAHFD model.